{"id":3618,"date":"2012-04-04T06:07:43","date_gmt":"2012-04-04T06:07:43","guid":{"rendered":"http:\/\/www.alohaber.net\/wp\/?p=3618"},"modified":"2012-04-04T06:07:43","modified_gmt":"2012-04-04T06:07:43","slug":"sosyal-guvenlik-kurumu-saglik-uygulama-tebliginde-degisiklik-yapilmasina-dair-teblig-12","status":"publish","type":"post","link":"https:\/\/www.alohaber.net\/wp\/2012\/04\/sosyal-guvenlik-kurumu-saglik-uygulama-tebliginde-degisiklik-yapilmasina-dair-teblig-12\/","title":{"rendered":"Sosyal G\u00fcvenlik Kurumu Sa\u011fl\u0131k Uygulama Tebli\u011finde De\u011fi\u015fiklik Yap\u0131lmas\u0131na Dair Tebli\u011f"},"content":{"rendered":"

\"\"<\/a>Sosyal G\u00fcvenlik Kurumu Sal\u0131k Uygulama Tebli\u011finin…<\/span><\/p>\n

 <\/p>\n

<\/p>\n

04 Nisan 2012 Tarihli Resmi Gazete<\/span><\/p>\n

Say\u0131: 28254 <\/span><\/p>\n

 <\/p>\n

Sosyal G<\/span>\u00fc<\/span>venlik Kurumundan:<\/span><\/p>\n

 <\/p>\n

SOSYAL G<\/strong><\/span>\u00dc<\/strong><\/span>VENL<\/strong><\/span>\u0130<\/strong><\/span>K KURUMU SA<\/strong><\/span>\u011e<\/strong><\/span>LIK UYGULAMA TEBL<\/strong><\/span>\u0130\u011e\u0130<\/strong><\/span>NDE DE<\/strong><\/span>\u011e\u0130\u015e\u0130<\/strong><\/span>KL<\/strong><\/span>\u0130<\/strong><\/span>K YAPILMASINA DA<\/strong><\/span>\u0130<\/strong><\/span>R TEBL<\/strong><\/span>\u0130\u011e<\/strong><\/span><\/p>\n

\u00a0<\/span><\/strong><\/p>\n

MADDE 1 <\/span>\u2013<\/span><\/strong>25\/3\/2010<\/span> tarihli ve 27532 say<\/span>\u0131<\/span>l<\/span>\u0131<\/span> m<\/span>\u00fc<\/span>kerrer Resm<\/span>\u00ee<\/span> Gazete<\/span>\u2019<\/span>de yay<\/span>\u0131<\/span>mlanan Sosyal G<\/span>\u00fc<\/span>venlik Kurumu Sa<\/span>\u011f<\/span>l<\/span>\u0131<\/span>k Uygulama Tebli<\/span>\u011f<\/span>inin 3.1.1.A-2. numaral<\/span>\u0131<\/span> maddesine a<\/span>\u015f<\/span>a<\/span>\u011f\u0131<\/span>daki f<\/span>\u0131<\/span>kra eklenmi<\/span>\u015f<\/span>tir.<\/span><\/p>\n

 <\/p>\n

\u201c<\/span>(6) Kurum gerekli g<\/span>\u00f6<\/span>rd<\/span>\u00fc\u011f\u00fc<\/span> hallerde, Sa<\/span>\u011f<\/span>l<\/span>\u0131<\/span>k Bakanl<\/span>\u0131\u011f\u0131<\/span> d<\/span>\u0131\u015f\u0131<\/span>ndaki resmi sa<\/span>\u011f<\/span>l<\/span>\u0131<\/span>k hizmeti sunucular<\/span>\u0131<\/span>na do<\/span>\u011f<\/span>rudan m<\/span>\u00fc<\/span>racaatlara ili<\/span>\u015f<\/span>kin ayr<\/span>\u0131<\/span>ca usul ve esas belirleyebilir.<\/span>\u201d<\/span><\/p>\n

 <\/p>\n

MADDE 2 <\/span>\u2013<\/span><\/strong>Ayn<\/span>\u0131<\/span> Tebli<\/span>\u011f<\/span>in 6.2.1.C-3 numaral<\/span>\u0131<\/span> maddesi a<\/span>\u015f<\/span>a<\/span>\u011f\u0131<\/span>daki <\/span>\u015f<\/span>ekilde de<\/span>\u011f<\/span>i<\/span>\u015f<\/span>tirilmi<\/span>\u015f<\/span>tir.<\/span><\/p>\n

 <\/p>\n

\u201c<\/span>6.2.1.C-3-<\/span>Abatasept<\/span><\/p>\n

 <\/p>\n

(1) <\/span>Romatoid<\/span>artritli<\/span> hastalarda, aktif <\/span>romatoid<\/span>artriti<\/span> bulunan biri <\/span>metotreksat<\/span> olmak <\/span>\u00fc<\/span>zere en az 3 farkl<\/span>\u0131<\/span> hastal<\/span>\u0131<\/span>k <\/span>modifiye<\/span> edici <\/span>antiromatizmal<\/span> ilac<\/span>\u0131<\/span>, en az 3<\/span>\u2019<\/span>er ay kullanm<\/span>\u0131\u015f<\/span> olmas<\/span>\u0131<\/span>na veya en az bir anti TNF tedavisine ra<\/span>\u011f<\/span>men hastal<\/span>\u0131\u011f\u0131<\/span> kontrol edilemeyen (DAS 28 SKORU>5.1 olan) eri<\/span>\u015f<\/span>kin hastalarda <\/span>metotreksat<\/span> ile birlikte, yaln<\/span>\u0131<\/span>zca <\/span>\u00fc<\/span>niversite veya e<\/span>\u011f<\/span>itim ve ara<\/span>\u015f<\/span>t<\/span>\u0131<\/span>rma hastanelerinde i<\/span>\u00e7<\/span>inde en az bir <\/span>romatoloji<\/span>, klinik <\/span>immunoloji<\/span> veya fiziksel t<\/span>\u0131<\/span>p ve <\/span>rehabilitasyon<\/span> uzman<\/span>\u0131<\/span>n<\/span>\u0131<\/span>n bulundu<\/span>\u011f<\/span>u 3 ay s<\/span>\u00fc<\/span>reli sa<\/span>\u011f<\/span>l<\/span>\u0131<\/span>k kurulu raporuna dayan<\/span>\u0131<\/span>larak bu uzman hekimler taraf<\/span>\u0131<\/span>ndan <\/span>re<\/span>\u00e7<\/span>etelenir<\/span>.<\/span><\/p>\n

 <\/p>\n

(2) <\/span>\u0130<\/span>laca ba<\/span>\u015f<\/span>land<\/span>\u0131<\/span>ktan 3 ay sonra yap<\/span>\u0131<\/span>lan de<\/span>\u011f<\/span>erlendirmede DAS 28<\/span>\u2019<\/span>te <\/span>0.6<\/span> puandan fazla d<\/span>\u00fc\u015f<\/span>me olmas<\/span>\u0131<\/span> halinde, bu durumun yeni d<\/span>\u00fc<\/span>zenlenecek 3 ay s<\/span>\u00fc<\/span>reli sa<\/span>\u011f<\/span>l<\/span>\u0131<\/span>k kurulu raporunda belirtilmesi ko<\/span>\u015f<\/span>ulu ile 3 ay daha tedaviye devam edilir.<\/span><\/p>\n

 <\/p>\n

(3) Bu raporun s<\/span>\u00fc<\/span>resi sonunda DAS 28<\/span>\u2019<\/span>te toplam 1,2 puandan fazla d<\/span>\u00fc\u015f<\/span>me olmas<\/span>\u0131<\/span> halinde bu durumun yeni d<\/span>\u00fc<\/span>zenlenecek 6 ay s<\/span>\u00fc<\/span>reli sa<\/span>\u011f<\/span>l<\/span>\u0131<\/span>k kurulu raporunda belirtilmesi ko<\/span>\u015f<\/span>ulu ile hastalar<\/span>\u0131<\/span>n tedavisine devam edilebilir.<\/span><\/p>\n

 <\/p>\n

(4) Tedavinin devam<\/span>\u0131<\/span>nda DAS 28 <\/span>kriterine<\/span> 6 ayda bir bak<\/span>\u0131<\/span>l<\/span>\u0131<\/span>r, ba<\/span>\u015f<\/span>lang<\/span>\u0131\u00e7<\/span> ve yeni DAS 28 skorlar<\/span>\u0131<\/span> her 6 ay s<\/span>\u00fc<\/span>reli sa<\/span>\u011f<\/span>l<\/span>\u0131<\/span>k kurulu raporunda belirtilir. Tedaviye ra<\/span>\u011f<\/span>men hastan<\/span>\u0131<\/span>n DAS 28 skorunda, ba<\/span>\u015f<\/span>lang<\/span>\u0131\u00e7<\/span> DAS 28 skoruna g<\/span>\u00f6<\/span>re, 1,2 puandan fazla d<\/span>\u00fc\u015f<\/span>me g<\/span>\u00f6<\/span>sterilemezse tedavi kesilir.<\/span>\u201d<\/span><\/p>\n

 <\/p>\n

MADDE 3 <\/span>\u2013<\/span><\/strong> Ayn<\/span>\u0131<\/span> Tebli<\/span>\u011f<\/span>in 6.2.28.A numaral<\/span>\u0131<\/span> maddesinin (2) numaral<\/span>\u0131<\/span> f<\/span>\u0131<\/span>kras<\/span>\u0131<\/span> y<\/span>\u00fc<\/span>r<\/span>\u00fc<\/span>rl<\/span>\u00fc<\/span>kten kald<\/span>\u0131<\/span>r<\/span>\u0131<\/span>lm<\/span>\u0131\u015f<\/span>t<\/span>\u0131<\/span>r.<\/span><\/p>\n

 <\/p>\n

MADDE 4 <\/span>\u2013<\/span><\/strong>Ayn<\/span>\u0131<\/span> Tebli<\/span>\u011f<\/span>in 6.2.33 numaral<\/span>\u0131<\/span> maddesinin (3) numaral<\/span>\u0131<\/span> f<\/span>\u0131<\/span>kras<\/span>\u0131<\/span> a<\/span>\u015f<\/span>a<\/span>\u011f\u0131<\/span>daki <\/span>\u015f<\/span>ekilde de<\/span>\u011f<\/span>i<\/span>\u015f<\/span>tirilmi<\/span>\u015f<\/span>tir.<\/span><\/p>\n

 <\/p>\n

\u201c<\/span>(3) <\/span>Ranibizumab<\/span>; hasta <\/span>anamnezi<\/span>, FFA ve lezyona ait renkli resim 3 ay s<\/span>\u00fc<\/span>reli sa<\/span>\u011f<\/span>l<\/span>\u0131<\/span>k kurulu rapora eklenerek birer ay arayla 3 kez y<\/span>\u00fc<\/span>kleme dozuyla ba<\/span>\u015f<\/span>lan<\/span>\u0131<\/span>r. Hastalar izlenerek g<\/span>\u00f6<\/span>z dibi bulgular<\/span>\u0131<\/span>, g<\/span>\u00f6<\/span>rme keskinli<\/span>\u011f<\/span>i ve optik <\/span>koherens<\/span>tomografileri<\/span> de<\/span>\u011f<\/span>erlendirilir ve tekrar tedavi gerekirse bu bulgular ve tedaviye devam karar<\/span>\u0131<\/span> her uygulama i<\/span>\u00e7<\/span>in d<\/span>\u00fc<\/span>zenlenecek yeni sa<\/span>\u011f<\/span>l<\/span>\u0131<\/span>k kurulu raporunda belirtilir.<\/span>\u201d<\/span><\/p>\n

 <\/p>\n

MADDE 5 <\/span>\u2013<\/span><\/strong>Ayn<\/span>\u0131<\/span> Tebli<\/span>\u011f<\/span>in 9.2.2. numaral<\/span>\u0131<\/span> maddesi a<\/span>\u015f<\/span>a<\/span>\u011f\u0131<\/span>daki <\/span>\u015f<\/span>ekilde de<\/span>\u011f<\/span>i<\/span>\u015f<\/span>tirilmi<\/span>\u015f<\/span>tir.<\/span><\/p>\n

 <\/p>\n

\u201c<\/span>9.2.2. Eczane Faturalar<\/span>\u0131<\/span>n<\/span>\u0131<\/span>n D<\/span>\u00fc<\/span>zenlenmesi;<\/span><\/p>\n

 <\/p>\n

(1) Eczaneler taraf<\/span>\u0131<\/span>ndan, her ay<\/span>\u0131<\/span>n ilk ve son g<\/span>\u00fc<\/span>n<\/span>\u00fc<\/span>n<\/span>\u00fc<\/span> kapsayan d<\/span>\u00f6<\/span>neme ait re<\/span>\u00e7<\/span>eteler, o ay<\/span>\u0131<\/span>n son g<\/span>\u00fc<\/span>n<\/span>\u00fc<\/span> tarihini ta<\/span>\u015f\u0131<\/span>yacak <\/span>\u015f<\/span>ekilde sonland<\/span>\u0131<\/span>r<\/span>\u0131<\/span>l<\/span>\u0131<\/span>r ve faturaland<\/span>\u0131<\/span>r<\/span>\u0131<\/span>l<\/span>\u0131<\/span>r.<\/span><\/p>\n

 <\/p>\n

a) Yabanc<\/span>\u0131<\/span>\u00fc<\/span>lkelerle yap<\/span>\u0131<\/span>lan sosyal g<\/span>\u00fc<\/span>venlik s<\/span>\u00f6<\/span>zle<\/span>\u015f<\/span>meleri kapsam<\/span>\u0131<\/span>nda kurum sa<\/span>\u011f<\/span>l<\/span>\u0131<\/span>k yard<\/span>\u0131<\/span>mlar<\/span>\u0131<\/span>ndan yararland<\/span>\u0131<\/span>r<\/span>\u0131<\/span>lan ve Sosyal G<\/span>\u00fc<\/span>venlik <\/span>\u0130<\/span>l M<\/span>\u00fc<\/span>d<\/span>\u00fc<\/span>rl<\/span>\u00fc<\/span>klerince d<\/span>\u00fc<\/span>zenlenmi<\/span>\u015f<\/span> ve onaylanm<\/span>\u0131\u015f<\/span> Sosyal G<\/span>\u00fc<\/span>venlik S<\/span>\u00f6<\/span>zle<\/span>\u015f<\/span>mesine G<\/span>\u00f6<\/span>re Sa<\/span>\u011f<\/span>l<\/span>\u0131<\/span>k Yard<\/span>\u0131<\/span>m Belgesi (asl<\/span>\u0131<\/span> veya fotokopisi) ile m<\/span>\u00fc<\/span>racaat eden ki<\/span>\u015f<\/span>ilerin re<\/span>\u00e7<\/span>etelerine ait faturalar <\/span>\u00fc<\/span>lke baz<\/span>\u0131<\/span>nda ayr<\/span>\u0131<\/span>ayr<\/span>\u0131<\/span> olmak <\/span>\u00fc<\/span>zere <\/span>manuel<\/span>,<\/span><\/p>\n

 <\/p>\n

b) Kurum bilgi i<\/span>\u015f<\/span>lem sisteminden hasta takip numaras<\/span>\u0131<\/span>\/<\/span>provizyon<\/span> al<\/span>\u0131<\/span>namamas<\/span>\u0131<\/span>na ra<\/span>\u011f<\/span>men sa<\/span>\u011f<\/span>l<\/span>\u0131<\/span>k yard<\/span>\u0131<\/span>mlar<\/span>\u0131<\/span> yeterli prim <\/span>\u00f6<\/span>deme g<\/span>\u00fc<\/span>n say<\/span>\u0131<\/span>s<\/span>\u0131<\/span> olmaks<\/span>\u0131<\/span>z<\/span>\u0131<\/span>n ve\/veya prim borcu olup olmad<\/span>\u0131\u011f\u0131<\/span>na bak<\/span>\u0131<\/span>lmaks<\/span>\u0131<\/span>z<\/span>\u0131<\/span>n Kurumca kar<\/span>\u015f\u0131<\/span>lanacak olan;<\/span><\/p>\n

 <\/p>\n

1- <\/span>\u0130\u015f<\/span> kazas<\/span>\u0131<\/span>na u<\/span>\u011f<\/span>rayan ki<\/span>\u015f<\/span>ilere ait faturalar her hasta i<\/span>\u00e7<\/span>in ayr<\/span>\u0131<\/span>ayr<\/span>\u0131<\/span> (sadece i<\/span>\u015f<\/span> kazas<\/span>\u0131<\/span> nedeniyle sunulan sa<\/span>\u011f<\/span>l<\/span>\u0131<\/span>k hizmeti bedelleri <\/span>\u00f6<\/span>denir) olmak <\/span>\u00fc<\/span>zere <\/span>manuel<\/span>,<\/span><\/p>\n

 <\/p>\n

2-<\/span>\u201c\u00d6<\/span>z<\/span>\u00fc<\/span>rl<\/span>\u00fc<\/span>l<\/span>\u00fc<\/span>k <\/span>\u00d6<\/span>l<\/span>\u00e7\u00fc<\/span>t<\/span>\u00fc<\/span>, S<\/span>\u0131<\/span>n<\/span>\u0131<\/span>fland<\/span>\u0131<\/span>r<\/span>\u0131<\/span>lmas<\/span>\u0131<\/span> ve <\/span>\u00d6<\/span>z<\/span>\u00fc<\/span>rl<\/span>\u00fc<\/span>lere Verilecek Sa<\/span>\u011f<\/span>l<\/span>\u0131<\/span>k Kurulu Raporlar<\/span>\u0131<\/span> Hakk<\/span>\u0131<\/span>nda Y<\/span>\u00f6<\/span>netmelik<\/span>\u201d<\/span> kapsam<\/span>\u0131<\/span>nda, yetkilendirilmi<\/span>\u015f<\/span>\u00f6<\/span>z<\/span>\u00fc<\/span>rl<\/span>\u00fc<\/span> sa<\/span>\u011f<\/span>l<\/span>\u0131<\/span>k kurulu raporu vermeye yetkili sa<\/span>\u011f<\/span>l<\/span>\u0131<\/span>k kurulu<\/span>\u015f<\/span>lar<\/span>\u0131<\/span>nca, a<\/span>\u011f\u0131<\/span>r <\/span>\u00f6<\/span>z<\/span>\u00fc<\/span>rl<\/span>\u00fc<\/span> oldu<\/span>\u011f<\/span>u <\/span>\u00f6<\/span>z<\/span>\u00fc<\/span>rl<\/span>\u00fc<\/span> sa<\/span>\u011f<\/span>l<\/span>\u0131<\/span>k kurulu raporu ile belgelendirilen t<\/span>\u0131<\/span>bben ba<\/span>\u015f<\/span>kas<\/span>\u0131<\/span>n<\/span>\u0131<\/span>n bak<\/span>\u0131<\/span>m<\/span>\u0131<\/span>na muhta<\/span>\u00e7<\/span> ki<\/span>\u015f<\/span>ilere ait faturalar her hasta i<\/span>\u00e7<\/span>in ayr<\/span>\u0131<\/span>ayr<\/span>\u0131<\/span> olmak <\/span>\u00fc<\/span>zere <\/span>manuel<\/span>,<\/span><\/p>\n

 <\/p>\n

3- Bildirimi zorunlu bula<\/span>\u015f\u0131<\/span>c<\/span>\u0131<\/span> hastal<\/span>\u0131<\/span>k tespit edilen ki<\/span>\u015f<\/span>ilere ait faturalar her hasta i<\/span>\u00e7<\/span>in ayr<\/span>\u0131<\/span>ayr<\/span>\u0131<\/span> olmak <\/span>\u00fc<\/span>zere <\/span>manuel<\/span>,<\/span><\/p>\n

 <\/p>\n

4- Acil haller nedeni ile sa<\/span>\u011f<\/span>l<\/span>\u0131<\/span>k yard<\/span>\u0131<\/span>mlar<\/span>\u0131<\/span>ndan yararland<\/span>\u0131<\/span>r<\/span>\u0131<\/span>lan ki<\/span>\u015f<\/span>ilere ait faturalar her hasta i<\/span>\u00e7<\/span>in ayr<\/span>\u0131<\/span>ayr<\/span>\u0131<\/span> olmak <\/span>\u00fc<\/span>zere <\/span>manuel<\/span>,<\/span><\/p>\n

 <\/p>\n

5- Koruyucu sa<\/span>\u011f<\/span>l<\/span>\u0131<\/span>k hizmetleri nedeni ile sa<\/span>\u011f<\/span>l<\/span>\u0131<\/span>k yard<\/span>\u0131<\/span>mlar<\/span>\u0131<\/span>ndan yararland<\/span>\u0131<\/span>r<\/span>\u0131<\/span>lan ki<\/span>\u015f<\/span>ilere ait faturalar her hasta i<\/span>\u00e7<\/span>in ayr<\/span>\u0131<\/span>ayr<\/span>\u0131<\/span> olmak <\/span>\u00fc<\/span>zere <\/span>manuel<\/span>,<\/span><\/p>\n

 <\/p>\n

6- Gebeli<\/span>\u011f<\/span>in ba<\/span>\u015f<\/span>lad<\/span>\u0131\u011f\u0131<\/span> tarihten itibaren do<\/span>\u011f<\/span>umdan sonraki ilk sekiz haftal<\/span>\u0131<\/span>k, <\/span>\u00e7<\/span>o<\/span>\u011f<\/span>ul gebelik halinde ise ilk on haftal<\/span>\u0131<\/span>k s<\/span>\u00fc<\/span>reye kadar olan gebelik ve anal<\/span>\u0131<\/span>k halini kapsayan anal<\/span>\u0131<\/span>k haliyle ilgili rahats<\/span>\u0131<\/span>zl<\/span>\u0131<\/span>k ve <\/span>\u00f6<\/span>z<\/span>\u00fc<\/span>rl<\/span>\u00fc<\/span>l<\/span>\u00fc<\/span>k hallerinde sa<\/span>\u011f<\/span>l<\/span>\u0131<\/span>k hizmeti sa<\/span>\u011f<\/span>lanan kad<\/span>\u0131<\/span>nlara ait faturalar, her hasta i<\/span>\u00e7<\/span>in ayr<\/span>\u0131<\/span>ayr<\/span>\u0131<\/span> olmak <\/span>\u00fc<\/span>zere <\/span>manuel<\/span>,<\/span><\/p>\n

 <\/p>\n

7- Meslek hastal<\/span>\u0131\u011f\u0131<\/span>na u<\/span>\u011f<\/span>rayan ki<\/span>\u015f<\/span>ilere ait faturalar her hasta i<\/span>\u00e7<\/span>in ayr<\/span>\u0131<\/span>ayr<\/span>\u0131<\/span>manuel<\/span>,<\/span><\/p>\n

 <\/p>\n

c) <\/span>\u0130\u015f<\/span> kazas<\/span>\u0131<\/span>, meslek hastal<\/span>\u0131\u011f\u0131<\/span>, trafik kazas<\/span>\u0131<\/span> ve adli vaka re<\/span>\u00e7<\/span>etelerine ait faturalar her hasta i<\/span>\u00e7<\/span>in ayr<\/span>\u0131<\/span>ayr<\/span>\u0131<\/span> olmak <\/span>\u00fc<\/span>zere,<\/span><\/p>\n

 <\/p>\n

\u00e7<\/span>) Yatan hasta re<\/span>\u00e7<\/span>eteleri, g<\/span>\u00fc<\/span>n<\/span>\u00fc<\/span>birlik tedavi re<\/span>\u00e7<\/span>eteleri ve sa<\/span>\u011f<\/span>l<\/span>\u0131<\/span>k raporu ile temin edilen ila<\/span>\u00e7<\/span>\/ila<\/span>\u00e7<\/span>lar<\/span>\u0131<\/span> i<\/span>\u00e7<\/span>eren re<\/span>\u00e7<\/span>etelere ait faturalar,<\/span><\/p>\n

 <\/p>\n

d) Kan <\/span>\u00fc<\/span>r<\/span>\u00fc<\/span>n<\/span>\u00fc<\/span> ve hemofili ilac<\/span>\u0131<\/span>\/ila<\/span>\u00e7<\/span>lar<\/span>\u0131<\/span> i<\/span>\u00e7<\/span>eren re<\/span>\u00e7<\/span>etelere ait faturalar,<\/span><\/p>\n

 <\/p>\n

e) <\/span>\u0130\u00e7<\/span>eri<\/span>\u011f<\/span>inde en az bir adet ge<\/span>\u00e7<\/span>ici <\/span>karekod<\/span> etiketli ila<\/span>\u00e7<\/span> bulunan re<\/span>\u00e7<\/span>etelere ait faturalar,<\/span><\/p>\n

 <\/p>\n

f) Eczanelerden ila<\/span>\u00e7<\/span> teminine ili<\/span>\u015f<\/span>kin mevzuatta ayr<\/span>\u0131<\/span> faturaland<\/span>\u0131<\/span>r<\/span>\u0131<\/span>lmas<\/span>\u0131<\/span>na dair d<\/span>\u00fc<\/span>zenleme yap<\/span>\u0131<\/span>lm<\/span>\u0131\u015f<\/span> re<\/span>\u00e7<\/span>etelere ait faturalar,<\/span><\/p>\n

 <\/p>\n

g) Yukar<\/span>\u0131<\/span>daki gruplar<\/span>\u0131<\/span>n d<\/span>\u0131\u015f\u0131<\/span>nda kalan re<\/span>\u00e7<\/span>etelere ait faturalar,<\/span><\/p>\n

 <\/p>\n

ayr<\/span>\u0131<\/span>ayr<\/span>\u0131<\/span>\u00fc\u00e7<\/span>er n<\/span>\u00fc<\/span>shal<\/span>\u0131<\/span> (bir n<\/span>\u00fc<\/span>shas<\/span>\u0131<\/span> eczac<\/span>\u0131<\/span> taraf<\/span>\u0131<\/span>ndan asl<\/span>\u0131<\/span> gibidir onayl<\/span>\u0131<\/span> fotokopi olabilir) alt gruplar halinde d<\/span>\u00fc<\/span>zenlenir.<\/span><\/p>\n

 <\/p>\n

(2) Birinci f<\/span>\u0131<\/span>kran<\/span>\u0131<\/span>n (a), (b), (c), (e) ve (f) bentlerinde belirtilen re<\/span>\u00e7<\/span>eteler hari<\/span>\u00e7<\/span> olmak <\/span>\u00fc<\/span>zere; i<\/span>\u00e7<\/span>eri<\/span>\u011f<\/span>inde en az bir raporlu ila<\/span>\u00e7<\/span>, kan <\/span>\u00fc<\/span>r<\/span>\u00fc<\/span>n<\/span>\u00fc<\/span> veya hemofili ilac<\/span>\u0131<\/span> bulunan re<\/span>\u00e7<\/span>eteler, ilgisine g<\/span>\u00f6<\/span>re (<\/span>\u00e7<\/span>) veya (d) bentlerinde belirtilen re<\/span>\u00e7<\/span>ete grubuna d<\/span>\u00e2<\/span>hil edilerek faturaland<\/span>\u0131<\/span>r<\/span>\u0131<\/span>lacakt<\/span>\u0131<\/span>r.<\/span>\u201d<\/span><\/p>\n

 <\/p>\n

MADDE 6 <\/span>\u2013<\/span><\/strong>Ayn<\/span>\u0131<\/span> Tebli<\/span>\u011f<\/span> eki <\/span>\u201c<\/span>Hasta Kat<\/span>\u0131<\/span>l<\/span>\u0131<\/span>m Pay<\/span>\u0131<\/span>ndan Muaf <\/span>\u0130<\/span>la<\/span>\u00e7<\/span>lar Listesi<\/span>\u201d<\/span>nde<\/span> (Ek-2) a<\/span>\u015f<\/span>a<\/span>\u011f\u0131<\/span>daki d<\/span>\u00fc<\/span>zenlemeler yap<\/span>\u0131<\/span>lm<\/span>\u0131\u015f<\/span>t<\/span>\u0131<\/span>r.<\/span><\/p>\n

 <\/p>\n

a) <\/span>\u201c<\/span>Kronik karaci<\/span>\u011f<\/span>er hastal<\/span>\u0131<\/span>klar<\/span>\u0131\u201d<\/span> ba<\/span>\u015f<\/span>l<\/span>\u0131<\/span>kl<\/span>\u0131<\/span> (<\/span>6.4<\/span>) numaral<\/span>\u0131<\/span> alt maddesine a<\/span>\u015f<\/span>a<\/span>\u011f\u0131<\/span>daki d<\/span>\u00fc<\/span>zenleme (6.4.6) numaral<\/span>\u0131<\/span> madde olarak ilave edilmi<\/span>\u015f<\/span>tir.<\/span><\/p>\n

 <\/p>\n

\u201c<\/span>6.4.6. <\/span>Antiviraller<\/span>\u201d<\/span><\/p>\n

 <\/p>\n

b) <\/span>\u201c<\/span>Demiyelinizan<\/span> hastal<\/span>\u0131<\/span>klar (<\/span>l<\/span>\u00f6<\/span>kodistrofi<\/span>, <\/span>multipl<\/span> skleroz v.b.)<\/span>\u201d<\/span> ba<\/span>\u015f<\/span>l<\/span>\u0131<\/span>kl<\/span>\u0131<\/span> (<\/span>10.5<\/span>) numaral<\/span>\u0131<\/span> alt maddesine a<\/span>\u015f<\/span>a<\/span>\u011f\u0131<\/span>daki d<\/span>\u00fc<\/span>zenleme (10.5.9) numaral<\/span>\u0131<\/span> madde olarak ilave edilmi<\/span>\u015f<\/span>tir.<\/span><\/p>\n

 <\/p>\n

\u201c<\/span>10.5.9. <\/span>Dalfampridine<\/span>*<\/span>\u201d<\/span><\/p>\n

 <\/p>\n

c) <\/span>\u201c<\/span>N<\/span>\u00f6<\/span>rojenik<\/span> mesane<\/span>\u201d<\/span> ba<\/span>\u015f<\/span>l<\/span>\u0131<\/span>kl<\/span>\u0131<\/span> (15.11) numaral<\/span>\u0131<\/span> alt maddesine a<\/span>\u015f<\/span>a<\/span>\u011f\u0131<\/span>daki d<\/span>\u00fc<\/span>zenleme (15.11.7) numaral<\/span>\u0131<\/span> madde olarak ilave edilmi<\/span>\u015f<\/span>tir.<\/span><\/p>\n

 <\/p>\n

\u201c<\/span>15.11.7. <\/span>Fesoterodin<\/span>\u201d<\/span><\/p>\n

 <\/p>\n

MADDE 7 <\/span>\u2013<\/span><\/strong>Ayn<\/span>\u0131<\/span> Tebli<\/span>\u011f<\/span> eki <\/span>\u201c<\/span>Sistemik <\/span>Antimikrobik<\/span> ve Di<\/span>\u011f<\/span>er <\/span>\u0130<\/span>la<\/span>\u00e7<\/span>lar<\/span>\u0131<\/span>n <\/span>Re<\/span>\u00e7<\/span>eteleme<\/span> Kurallar<\/span>\u0131<\/span> Listesi<\/span>\u201d<\/span>nde (Ek-2\/A) <\/span>\u201c<\/span>Di<\/span>\u011f<\/span>erleri<\/span>\u201d<\/span> ba<\/span>\u015f<\/span>l<\/span>\u0131<\/span>kl<\/span>\u0131<\/span> (13) numaral<\/span>\u0131<\/span> maddesine a<\/span>\u015f<\/span>a<\/span>\u011f\u0131<\/span>daki d<\/span>\u00fc<\/span>zenleme (24) numaral<\/span>\u0131<\/span> alt madde olarak ilave edilmi<\/span>\u015f<\/span>tir.<\/span><\/p>\n

 <\/p>\n

\n\n\n\n
24<\/span><\/td>\nAsetilsistein<\/span><\/td>\nKY (<\/span>600 <\/span>mg\u2019\u0131n<\/span> \u00fczerindeki dozlar\u0131<\/span> uzman hekimlerince <\/span>re\u00e7etelenir<\/span>)<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

\n

MADDE 8 <\/span>\u2013<\/span><\/strong>Ayn<\/span>\u0131<\/span> Tebli<\/span>\u011f<\/span> eki <\/span>\u201c<\/span>Sadece Yatan Hastalarda Kullan<\/span>\u0131<\/span>m<\/span>\u0131<\/span> Halinde Bedelleri <\/span>\u00d6<\/span>denecek <\/span>\u0130<\/span>la<\/span>\u00e7<\/span>lar Listesi<\/span>\u201d<\/span>nin (Ek-2\/B) (40) numaral<\/span>\u0131<\/span> maddesi a<\/span>\u015f<\/span>a<\/span>\u011f\u0131<\/span>daki <\/span>\u015f<\/span>ekilde de<\/span>\u011f<\/span>i<\/span>\u015f<\/span>tirilmi<\/span>\u015f<\/span>tir.<\/span><\/p>\n

 <\/p>\n

\u201c<\/span>40. <\/span>\u0130<\/span>ntraven<\/span>\u00f6<\/span>z<\/span> Anti <\/span>Rh<\/span> Preparatlar<\/span>\u0131<\/span> (Ayaktan tedavide; <\/span>SUT<\/span>\u2019<\/span>un<\/span> 6.2.27-B maddesi esaslar<\/span>\u0131<\/span>na g<\/span>\u00f6<\/span>re)<\/span>\u201d<\/span><\/p>\n

 <\/p>\n

MADDE 9 <\/span>\u2013<\/span><\/strong>Ayn<\/span>\u0131<\/span> Tebli<\/span>\u011f<\/span> eki <\/span>\u201c<\/span>Ayakta Tedavide Sa<\/span>\u011f<\/span>l<\/span>\u0131<\/span>k Raporu (Uzman Hekim Raporu\/Sa<\/span>\u011f<\/span>l<\/span>\u0131<\/span>k Kurulu Raporu) ile Verilebilecek <\/span>\u0130<\/span>la<\/span>\u00e7<\/span>lar Listesi<\/span>\u201d<\/span>nde (Ek-2\/C) a<\/span>\u015f<\/span>a<\/span>\u011f\u0131<\/span>daki d<\/span>\u00fc<\/span>zenlemeler yap<\/span>\u0131<\/span>lm<\/span>\u0131\u015f<\/span>t<\/span>\u0131<\/span>r.<\/span><\/p>\n

 <\/p>\n

a) (45) numaral<\/span>\u0131<\/span> maddesi a<\/span>\u015f<\/span>a<\/span>\u011f\u0131<\/span>daki <\/span>\u015f<\/span>ekilde de<\/span>\u011f<\/span>i<\/span>\u015f<\/span>tirilmi<\/span>\u015f<\/span>tir.<\/span><\/p>\n

 <\/p>\n

\u201c<\/span>Solifenasin<\/span>, <\/span>Tolterodine<\/span>-L, <\/span>Trospiyum<\/span>, <\/span>Darifenasin<\/span>, <\/span>Propiverin<\/span>, <\/span>Fesoterodin<\/span>; <\/span>Oksibutinine<\/span> yan<\/span>\u0131<\/span>t al<\/span>\u0131<\/span>namayan ya da <\/span>tolere<\/span> edemeyen hastalarda t<\/span>\u00fc<\/span>m uzman hekimler taraf<\/span>\u0131<\/span>ndan, uzman hekimlerce d<\/span>\u00fc<\/span>zenlenen rapora dayan<\/span>\u0131<\/span>larak t<\/span>\u00fc<\/span>m hekimlerce re<\/span>\u00e7<\/span>ete edilir.<\/span>\u201d<\/span><\/p>\n

 <\/p>\n

b) (52) numaral<\/span>\u0131<\/span> maddesi y<\/span>\u00fc<\/span>r<\/span>\u00fc<\/span>rl<\/span>\u00fc<\/span>kten kald<\/span>\u0131<\/span>r<\/span>\u0131<\/span>lm<\/span>\u0131\u015f<\/span>t<\/span>\u0131<\/span>r.<\/span><\/p>\n

 <\/p>\n

MADDE 10 <\/span>\u2013<\/span><\/strong>Bu Tebli<\/span>\u011f<\/span>in;<\/span><\/p>\n

 <\/p>\n

a) 3 <\/span>\u00fc<\/span>nc<\/span>\u00fc<\/span> maddesi <\/span>2\/3\/2012<\/span> tarihinde,<\/span><\/p>\n

b) 4 <\/span>\u00fc<\/span>nc<\/span>\u00fc<\/span> maddesi <\/span>1\/2\/2012<\/span> tarihinde,<\/span><\/p>\n

c) 2, 6, 7, 8, 9 uncu maddeleri yay<\/span>\u0131<\/span>m<\/span>\u0131<\/span> tarihinden 5 i<\/span>\u015f<\/span> g<\/span>\u00fc<\/span>n<\/span>\u00fc<\/span> sonra,<\/span><\/p>\n

\u00e7<\/span>) Di<\/span>\u011f<\/span>er maddeleri yay<\/span>\u0131<\/span>m<\/span>\u0131<\/span> tarihinde,<\/span><\/p>\n

 <\/p>\n

y<\/span>\u00fc<\/span>r<\/span>\u00fc<\/span>rl<\/span>\u00fc\u011f<\/span>e<\/span> girer.<\/span><\/p>\n

 <\/p>\n

MADDE 11 <\/span>\u2013<\/span><\/strong>Bu Tebli<\/span>\u011f<\/span> h<\/span>\u00fc<\/span>k<\/span>\u00fc<\/span>mlerini Sosyal G<\/span>\u00fc<\/span>venlik Kurumu Ba<\/span>\u015f<\/span>kan<\/span>\u0131<\/span> y<\/span>\u00fc<\/span>r<\/span>\u00fc<\/span>t<\/span>\u00fc<\/span>r.<\/span><\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Sosyal G\u00fcvenlik Kurumu Sal\u0131k Uygulama Tebli\u011finin…  <\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-3618","post","type-post","status-publish","format-standard","hentry","category-mevzuat-haberleri"],"_links":{"self":[{"href":"https:\/\/www.alohaber.net\/wp\/wp-json\/wp\/v2\/posts\/3618","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.alohaber.net\/wp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.alohaber.net\/wp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.alohaber.net\/wp\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.alohaber.net\/wp\/wp-json\/wp\/v2\/comments?post=3618"}],"version-history":[{"count":1,"href":"https:\/\/www.alohaber.net\/wp\/wp-json\/wp\/v2\/posts\/3618\/revisions"}],"predecessor-version":[{"id":3619,"href":"https:\/\/www.alohaber.net\/wp\/wp-json\/wp\/v2\/posts\/3618\/revisions\/3619"}],"wp:attachment":[{"href":"https:\/\/www.alohaber.net\/wp\/wp-json\/wp\/v2\/media?parent=3618"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.alohaber.net\/wp\/wp-json\/wp\/v2\/categories?post=3618"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.alohaber.net\/wp\/wp-json\/wp\/v2\/tags?post=3618"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}